Join to access to all OVN content. Join for Free
The Value of In-House Medical Affairs to the MSL E205 • May 14, 2024 • 29 mins
MSLs in-house medical affairs HQ medical affairs Medical Science Liaison career advice

The Value of In-House Medical Affairs to the MSL E205 • May 14, 2024 • 29 mins


Share This Article


Summary

Erlene Seymour, Medical Director, US Medical Affairs Hematology at BeiGene discusses the value of In House or HQ Medical Affairs to the MSL.

Learn more about…

👉 Why is it important for MSLs to know about their inhouse counterparts and what comes from their support
👉 What makes in house medical affairs so valuable to MSLs and to the organization
👉 Advice for MSLs in how they should view and interact with their inhouse counterparts
👉 Advice for MSLs that may want to pursue a role in house or HQ medical affairs position
👉 What is it that helps MSLs stand out and separate themselves from the others

Click for Source
MSLs, in-house medical affairs, HQ medical affairs, Medical Science Liaison, career advice

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Article
The Four Employment Agreement Questions Every Pharma Executive Must Ask
Partner Avatar Michael Pietrack

The Four Employment Agreement Questions Every Pharma Executive Must Ask

Podcast
Social Media Listening Evolved
Partner Avatar MSL Talk: Tom Caravela, Conor McGladrigan, Kevin Peterson

Social Media Listening Evolved

Podcast
Over-Negotiation-How to Botch a Job Offer
Partner Avatar MSL Talk: Tom Caravela

Over-Negotiation-How to Botch a Job Offer

Article
Does biomarker use in oncology improve clinical trial failure risk? A large-scale analysis
OVN Avatar Jayson L. Parker, Sebnem S. Kuzulugil, Kirill Pereverzev, Stephen Mac, Gilberto Lopes, Zain Shah, Ashini Weerasinghe, Daniel Rubinger, Adam Falconi, Ayse Bener, Bora Caglayan, Rohan Tangri, Nicholas Mitsakakis

Does biomarker use in oncology improve clinical trial failure risk? A large-scale analysis

Article
Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval
OVN Avatar Avi Cherla, MSc; Huseyin Naci, MHS, PhD; Aaron S. Kesselheim, MD, JD, MPH; Bishal Gyawali, MD, PhD; Elias Mossialos, MD, PhD

Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval

Article
Assessment of Food and Drug Administration- and European Medicines Agency-Approved Systemic Oncology Therapies and Clinically Meaningful Improvements in Quality of Life: A Systematic Review
OVN Avatar Vanessa Arciero, BS, Seanthel Delos Santos, Liza Koshy

Assessment of Food and Drug Administration- and European Medicines Agency-Approved Systemic Oncology Therapies and Clinically Meaningful Improvements in Quality of Life: A Systematic Review

Explore OVN